Fremgangsmåte ved fremstilling av antistoff- superantigenkonjugater

A soluble antibody conjugate comprising an antibody linked to a structure which is recognizable by T-cells and has the ability to direct T-cells to lyse the target cell, which is recognized by the antibody. The conjugate is characterized by the structure being a superantigen. One important mode is a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	AAKERBLOM, EVA, KALLAND, TERJE, HEDLUND, GUNNAR, LANDO, PETER, DOHLSTEN, MIKAEL
Format:	Patent
Sprache:	nor
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	AAKERBLOM, EVA KALLAND, TERJE HEDLUND, GUNNAR LANDO, PETER DOHLSTEN, MIKAEL
description	A soluble antibody conjugate comprising an antibody linked to a structure which is recognizable by T-cells and has the ability to direct T-cells to lyse the target cell, which is recognized by the antibody. The conjugate is characterized by the structure being a superantigen. One important mode is a method for the lysis of target cells, wherein the target cells are contacted with a target cell lysis effective amount of the conjugate. The method of lysis is part of a potent treatment regimen for cancer, autoimmunity, parasitic infestations and fungal, viral and bacterial infections. The specification also describes modes such as the synthesis of the conjugate and pharmaceutical compositions and their manufacture.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NO312816BB1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NO312816BB1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NO312816BB13</originalsourceid><addsrcrecordid>eNrjZHBxK0rNTU_MSy_OPby0JFWhLDVFIQ0oVFySmZOTmZeukFimkJhXkllckp-WpqtQXFqQWgTip6fmZefnZZWmJ5akFvEwsKYl5hSn8kJpbgYFN9cQZw_d1IL8-NTigsTk1LzUkng_f2NDIwtDMycnQ2MilAAAKdE0Sw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Fremgangsmåte ved fremstilling av antistoff- superantigenkonjugater</title><source>esp@cenet</source><creator>AAKERBLOM, EVA ; KALLAND, TERJE ; HEDLUND, GUNNAR ; LANDO, PETER ; DOHLSTEN, MIKAEL</creator><creatorcontrib>AAKERBLOM, EVA ; KALLAND, TERJE ; HEDLUND, GUNNAR ; LANDO, PETER ; DOHLSTEN, MIKAEL</creatorcontrib><description>A soluble antibody conjugate comprising an antibody linked to a structure which is recognizable by T-cells and has the ability to direct T-cells to lyse the target cell, which is recognized by the antibody. The conjugate is characterized by the structure being a superantigen. One important mode is a method for the lysis of target cells, wherein the target cells are contacted with a target cell lysis effective amount of the conjugate. The method of lysis is part of a potent treatment regimen for cancer, autoimmunity, parasitic infestations and fungal, viral and bacterial infections. The specification also describes modes such as the synthesis of the conjugate and pharmaceutical compositions and their manufacture.</description><edition>7</edition><language>nor</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2002</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20020708&DB=EPODOC&CC=NO&NR=312816B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20020708&DB=EPODOC&CC=NO&NR=312816B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>AAKERBLOM, EVA</creatorcontrib><creatorcontrib>KALLAND, TERJE</creatorcontrib><creatorcontrib>HEDLUND, GUNNAR</creatorcontrib><creatorcontrib>LANDO, PETER</creatorcontrib><creatorcontrib>DOHLSTEN, MIKAEL</creatorcontrib><title>Fremgangsmåte ved fremstilling av antistoff- superantigenkonjugater</title><description>A soluble antibody conjugate comprising an antibody linked to a structure which is recognizable by T-cells and has the ability to direct T-cells to lyse the target cell, which is recognized by the antibody. The conjugate is characterized by the structure being a superantigen. One important mode is a method for the lysis of target cells, wherein the target cells are contacted with a target cell lysis effective amount of the conjugate. The method of lysis is part of a potent treatment regimen for cancer, autoimmunity, parasitic infestations and fungal, viral and bacterial infections. The specification also describes modes such as the synthesis of the conjugate and pharmaceutical compositions and their manufacture.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2002</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHBxK0rNTU_MSy_OPby0JFWhLDVFIQ0oVFySmZOTmZeukFimkJhXkllckp-WpqtQXFqQWgTip6fmZefnZZWmJ5akFvEwsKYl5hSn8kJpbgYFN9cQZw_d1IL8-NTigsTk1LzUkng_f2NDIwtDMycnQ2MilAAAKdE0Sw</recordid><startdate>20020708</startdate><enddate>20020708</enddate><creator>AAKERBLOM, EVA</creator><creator>KALLAND, TERJE</creator><creator>HEDLUND, GUNNAR</creator><creator>LANDO, PETER</creator><creator>DOHLSTEN, MIKAEL</creator><scope>EVB</scope></search><sort><creationdate>20020708</creationdate><title>Fremgangsmåte ved fremstilling av antistoff- superantigenkonjugater</title><author>AAKERBLOM, EVA ; KALLAND, TERJE ; HEDLUND, GUNNAR ; LANDO, PETER ; DOHLSTEN, MIKAEL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NO312816BB13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>nor</language><creationdate>2002</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>AAKERBLOM, EVA</creatorcontrib><creatorcontrib>KALLAND, TERJE</creatorcontrib><creatorcontrib>HEDLUND, GUNNAR</creatorcontrib><creatorcontrib>LANDO, PETER</creatorcontrib><creatorcontrib>DOHLSTEN, MIKAEL</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>AAKERBLOM, EVA</au><au>KALLAND, TERJE</au><au>HEDLUND, GUNNAR</au><au>LANDO, PETER</au><au>DOHLSTEN, MIKAEL</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Fremgangsmåte ved fremstilling av antistoff- superantigenkonjugater</title><date>2002-07-08</date><risdate>2002</risdate><abstract>A soluble antibody conjugate comprising an antibody linked to a structure which is recognizable by T-cells and has the ability to direct T-cells to lyse the target cell, which is recognized by the antibody. The conjugate is characterized by the structure being a superantigen. One important mode is a method for the lysis of target cells, wherein the target cells are contacted with a target cell lysis effective amount of the conjugate. The method of lysis is part of a potent treatment regimen for cancer, autoimmunity, parasitic infestations and fungal, viral and bacterial infections. The specification also describes modes such as the synthesis of the conjugate and pharmaceutical compositions and their manufacture.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	nor
recordid	cdi_epo_espacenet_NO312816BB1
source	esp@cenet
subjects	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	Fremgangsmåte ved fremstilling av antistoff- superantigenkonjugater
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A02%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=AAKERBLOM,%20EVA&rft.date=2002-07-08&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENO312816BB1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true